Kerala Ayurveda (BSE 530163)₹163.35+5.76%Pharmaceuticals
In the Jun 2026 quarter (consolidated), Kerala Ayurveda reported sales of ₹33.22 Cr, up 15.9% from Jun 2025, and net profit of −₹8.09 Cr, down 500.5% year on year. For the year to Mar 2026, sales were ₹131 Cr and net profit −₹16.01 Cr.
Company filings, consolidated accounts; latest reported quarter Jun 2026
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 25.04 | 26.34 | 32.08 | 27.48 | 30.45 | 31.14 | 31.33 | 28.66 | 34.89 | 33.01 | 34.79 | 33.22 |
| Expenses | 24.48 | 25.32 | 26.60 | 26.68 | 24.87 | 32.31 | 41.45 | 32.81 | 39.78 | 34.46 | 41.85 | 37.03 |
| Operating Profit | 0.55 | 1.02 | 5.46 | 0.81 | 5.54 | −1.20 | −10.15 | −4.20 | −4.96 | −1.52 | −7.11 | −3.84 |
| OPM % | 2.2% | 3.9% | 17.0% | 2.9% | 18.2% | −3.8% | −32.4% | −14.7% | −14.2% | −4.6% | −20.4% | −11.5% |
| Other Income | 0.76 | 0.22 | −0.85 | 0.21 | 0.63 | 0.22 | 0.72 | 9.46 | 1.69 | 1.12 | 1.90 | 0.25 |
| Interest | 0.66 | 0.62 | 3.27 | 0.47 | 0.73 | 0.44 | 2.49 | 0.83 | 2.59 | 2.85 | 1.11 | 2.80 |
| Depreciation | 0.31 | 0.33 | 1.14 | 0.37 | 1.97 | 0.71 | 1.91 | 1.64 | 0.98 | 1.14 | 1.68 | 1.86 |
| Profit before tax | 0.35 | 0.30 | 0.19 | 0.21 | 3.48 | −2.12 | −13.85 | 2.82 | −6.84 | −4.38 | −8.00 | −8.25 |
| Tax % | 100.0% | 368.9% | −194.5% | −125.0% | −4.9% | 28.0% | 11.3% | 27.7% | −6.7% | 5.2% | −7.4% | −1.8% |
| Exceptional items | 0.00 | 0.00 | −1.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Profit | 0.00 | −0.80 | 0.54 | 0.47 | 3.66 | −2.71 | −15.39 | 2.02 | −6.35 | −4.61 | −7.40 | −8.09 |
| EPS (Rs) | −0.13 | −0.91 | 0.23 | 0.28 | 2.85 | −2.41 | −12.96 | 1.66 | −5.28 | −3.70 | −5.98 | −6.16 |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 46.06 | 50.05 | 59.01 | 59.06 | 77.01 | 62.07 | 80.06 | 93.07 | 108 | 126 | 131 | 136 |
| Expenses | 38.01 | 43.03 | 50.98 | 54.05 | 68.97 | 61.03 | 71.01 | 91.08 | 100 | 131 | 149 | 153 |
| Operating Profit | 8.01 | 7.01 | 8.01 | 5.01 | 7.01 | 1.01 | 10.01 | 3.01 | 9.01 | −5.01 | −18.02 | −17.43 |
| OPM % | 16.0% | 14.0% | 14.0% | 9.0% | 10.0% | 1.4% | 12.0% | 2.8% | 8.0% | −4.0% | −14.0% | −12.8% |
| Other Income | 0.00 | 0.00 | 0.00 | 0.99 | 0.00 | 0.00 | 0.99 | 2.99 | 0.00 | 1.99 | 13.99 | 4.96 |
| Interest | 2.01 | 1.01 | 2.01 | 3.01 | 2.01 | 6.02 | 7.03 | 5.02 | 6.02 | 4.01 | 7.03 | 9.35 |
| Depreciation | 1.99 | 1.99 | 2.01 | 0.99 | 0.99 | 0.99 | 0.99 | 0.99 | 1.99 | 4.99 | 4.99 | 5.66 |
| Profit before tax | 4.01 | 4.01 | 4.01 | 3.01 | 5.01 | −7.02 | 3.01 | −1.01 | 1.01 | −12.04 | −16.04 | −27.47 |
| Tax % | 33.0% | 22.0% | 31.0% | 19.0% | 11.0% | −28.0% | 15.0% | −23.0% | 185.0% | 14.0% | 0.0% | — |
| Exceptional items | 0.00 | 0.00 | 0.00 | 1.09 | 0.00 | 0.00 | 0.67 | 2.08 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Profit | 3.01 | 3.01 | 3.01 | 3.01 | 3.99 | −5.01 | 2.01 | 0.00 | −1.01 | −14.01 | −16.01 | −26.45 |
| EPS (Rs) | 2.57 | 2.91 | 2.67 | 2.32 | 3.70 | −4.60 | 2.25 | −0.86 | −0.48 | −11.64 | −12.77 | −21.12 |
| Dividend payout % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 11.01 | 11.01 | 11.01 | 11.00 | 11.00 | 11.00 | 11.01 | 10.99 | 11.00 | 11.98 | 11.98 | 12.99 |
| Reserves | −19.01 | −17.01 | −4.01 | −3.01 | −7.00 | −3.00 | −7.00 | −4.00 | −5.00 | 7.03 | −3.01 | −2.01 |
| Borrowings | 70.05 | 69.02 | 56.01 | 74.97 | 61.99 | 63.97 | 77.03 | 69.95 | 71.97 | 75.94 | 70.93 | 85.98 |
| Other Liabilities | 11.04 | 11.06 | 17.09 | 20.10 | 27.13 | 31.14 | 34.16 | 34.16 | 37.18 | 38.18 | 49.24 | 41.20 |
| Total Liabilities | 73.09 | 73.08 | 81.10 | 103 | 92.12 | 103 | 114 | 110 | 115 | 133 | 129 | 138 |
| Fixed Assets | 33.08 | 34.10 | 34.09 | 32.07 | 33.08 | 33.11 | 33.11 | 44.11 | 46.09 | 41.11 | 47.14 | 50.10 |
| CWIP | 0.00 | 0.00 | 6.02 | 11.04 | 12.05 | 14.05 | 14.05 | 4.02 | 7.03 | 7.03 | 9.03 | 8.03 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Assets | 40.01 | 38.98 | 40.99 | 58.95 | 46.99 | 55.95 | 68.04 | 61.97 | 61.03 | 84.99 | 72.97 | 81.03 |
| Inventories | 6.19 | 5.97 | 9.70 | 10.47 | 11.60 | 12.85 | 11.02 | 11.99 | 12.51 | 12.29 | 12.98 | 15.13 |
| Trade receivables | 3.71 | 4.18 | 4.79 | 5.43 | 6.88 | 10.69 | 10.30 | 13.30 | 12.92 | 17.37 | 19.26 | 13.77 |
| Cash & equivalents | 2.37 | 2.28 | 3.09 | 6.73 | 4.56 | 6.38 | 18.59 | 2.88 | 3.21 | 22.84 | 3.40 | 5.76 |
| Total Assets | 73.09 | 73.08 | 81.10 | 103 | 92.12 | 103 | 114 | 110 | 115 | 133 | 129 | 138 |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operating activity | 0.00 | 6.02 | 4.01 | −10.03 | 12.02 | 5.01 | 7.02 | 0.00 | 10.01 | −1.01 | 5.01 | −24.03 |
| Cash from investing activity | 0.00 | −2.99 | −2.99 | −2.99 | −2.99 | −3.99 | −0.99 | −1.99 | −6.99 | 0.00 | −14.97 | −4.98 |
| Cash from financing activity | 2.01 | −2.01 | 0.00 | 17.03 | −12.02 | 1.01 | 6.01 | −13.01 | −2.01 | 20.03 | −9.01 | 32.06 |
| Net cash flow | 1.99 | 0.00 | 0.99 | 3.99 | −1.99 | 1.99 | 11.99 | −15.99 | 0.00 | 17.99 | −18.99 | 2.99 |
| Capex | 0.36 | 3.27 | 1.87 | 5.48 | 2.45 | 3.34 | 1.03 | 2.84 | 6.17 | 1.08 | 13.30 | 5.61 |
| Free cash flow | 0.00 | 2.01 | 3.01 | −16.01 | 10.01 | 1.99 | 6.01 | −3.01 | 4.01 | −1.99 | −8.01 | −30.02 |
| CFO / OP % | 8.1% | 73.1% | 62.1% | −119.9% | 251.1% | 71.1% | 885.1% | −5.0% | 390.1% | 1.0% | −137.9% | 136.1% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor days | 36 | 34 | 36 | 35 | 44 | 52 | 62 | 62 | 52 | 60 | 57 | 39 |
| Inventory days | 287 | 227 | 319 | 338 | 311 | 313 | 268 | 254 | 227 | 205 | 208 | 200 |
| Days payable | 150 | 100 | 112 | 125 | 117 | 162 | 149 | 168 | 137 | 114 | 93 | 129 |
| Cash conversion cycle | 172 | 160 | 242 | 247 | 236 | 202 | 179 | 147 | 141 | 149 | 171 | 109 |
| Working capital days | −132 | −104 | −214 | −64 | −25 | −20 | −100 | −119 | −82 | −173 | −148 | −163 |
| ROCE % | 8.0% | 9.0% | 9.0% | 9.0% | 6.0% | 9.0% | 0.0% | 11.0% | 2.0% | 8.0% | −9.0% | −10.0% |
For the Jun 2026 quarter, Kerala Ayurveda reported sales of ₹33.22 Cr, up 15.9% year on year and net profit of −₹8.09 Cr, down 500.5% year on year. The operating margin was −11.5%.
Kerala Ayurveda's sales for the year to Mar 2026 were ₹131 Cr; over the last twelve months they were ₹136 Cr.
Net profit for the year to Mar 2026 was −₹16.01 Cr, and −₹26.45 Cr over the last twelve months. Earnings per share over the same trailing period were ₹−21.12.
Kerala Ayurveda reported borrowings of ₹85.98 Cr at Mar 2026, against cash and equivalents of ₹5.76 Cr.
Cash from operations was −₹24.03 Cr in the year to Mar 2026; after capital spending, free cash flow was −₹30.02 Cr.